Health economics is not just about reimbursement. It is about proving how a technology reduces the total cost of care.
In this episode, Betty Tsai, President of Cardiology Services International, explains why medtech companies must think beyond existing CPT or MS-DRG codes when shaping their commercialization strategies. Speaking with Saul at the MedTech Innovator event, she highlights how health economics reveals the true cost of a patient journey, from initial admission through readmissions and long-term care. Betty explores how value-based care and CMS performance metrics are reshaping hospital revenue and influencing adoption decisions. She also discusses alternative reimbursement pathways, such as the New Technology Add-on Payment, and emphasizes that companies demonstrating both clinical and economic value are more attractive to providers and investors.
Tune in and learn why proving economic value may be one of the most important steps in driving medtech adoption.
Resources:
- Connect with and follow Betty Tsai on LinkedIn.